APPROACH TO THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CARCINOMA: A SINGLE CENTER EXPERIENCE

Objevtive: Prostate cancer is the the second common cancer in men in Turkey. We aimed to share our single center experience on the characteristics of patients with metastatic castration sensitive prostate cancer (mCSPC) and the factors affecting survival. Material and Methods: In this retrospective cross-sectional study, 280 patients (aged 18 years and older men) who applied with the diagnosis of metastatic prostate carcinoma were screened between January 2007 and December 2020. Sociodemographic and clinicopathological characteristics of the patients were obtained retrospectively from the hospital database. The study variables of the research were included descriptive characteristics of the patients, metastasis sites, treatment approachs, comorbidities of the patients and overall survival (OS) were evaluated. The descriptive statistics, Chi-Square Test, Fisher Exact Test, Kaplan Meier, and Cox Regression models were used as appropriate for the statistical analysis. Results: A total of 201 patient who applied with the diagnosis of mCSPC were included in this study. The median age of the patients at the time of diagnosis was 68.67 years (43,97-90,48), 43.56% (n=88) of the patients were >= 70 years old and 56.43% (n=114) were under 70 years of age. The median follow-up time was 55.5 months, and the median OS was found to be 34.93 months (27.90-41.96). 34.7% of the patients were still alive at the time of date cutoff. The median OS of the patients was found to be significantly lower in individuals >= 70 years old than under 70 years of age (p=0.032). According to the LATITUDE study the median OS of the high-risk group (26.56 months) was statistically significantly lower than in the low-risk group (44.83 months). When the patients were evaluated in terms of disease volume according to CHAARTED, it was found that the median OS of the patient group with high-volume disease (29.03 months) was statistically significantly lower than the group with low-volume disease (46.80 months) (p=0.001). Conclusion: In this study, it was shown that being over 70 years old, a low BMI, high volume disease defined as in the CHAARTED trial, and high risk disease defined as in the LATITUDE trial had a negative impact on survival of patients with mCSPC.